Meeting Report

2020–2021 Drug Updates in Hematologic Malignancies

Kirollos Hanna, PharmD, BCPS, BCOP

From M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota

Presenter’s disclosure of conflicts of interest is found at the end of this article.


J Adv Pract Oncol 2022;13(3):282–285 | https://doi.org/10.6004/jadpro.2022.13.3.20 | © 2022 Harborside™


  

ABSTRACT

During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat patients safely with these new and approved therapeutic agents. In particular, CAR T-cell therapies were approved across many hematologic malignancies, along with PI3K inhibitors, anti-CD38 monoclonal antibodies, and immunotherapies.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.